Clinical Trials Arena November 11, 2024
The loan facility comprises up to four tranches, with a $30m tranche already drawn at closing and further funds available through H2 2026.
Disc Medicine (Disc) has secured a $200m non-dilutive term loan facility from Hercules Capital to advance the clinical trials of assets across its portfolio.
Through the financing, the company also aims to further bolster its financial and operational flexibility.
The loan facility comprises up to four tranches, with a $30m tranche already drawn at closing and further funds available through H2 2026 at Disc’s option.
An additional $80m is available at Disc’s discretion, with another $65m contingent on attaining certain performance milestones.
The final tranche of $25m will be accessible during the interest-only period, subject to the...
Today's Sponsors
Today's Sponsor